不同年龄段儿童耐药重症肺炎支原体肺炎的临床特征分析<sup>*</sup>

doi:10.3969/j.issn.1671-7171.2026.06.001

Abstract
Figure/Table
References (0)
Related Citation (15)

Download: PDF (1279 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract 【Objective】 To analyze the clinical characteristics of drug-resistant severe Mycoplasma pneumoniae pneumonia (MPP) in children of different age groups. 【Methods】 A retrospective analysis was performed on the clinical data of 207 children diagnosed with drug-resistant severe MPP admitted to The First Affiliated Hospital of Hunan Normal University (Hunan Provincial People's Hospital) from August 2023 to April 2024. The enrolled children were divided into three groups according to age: infant group (age<3 years old, n=40), preschool group (age 3-6 years old, n=73) and school-age group (age>6 years old, n=94). The clinical characteristics were compared among the three groups. 【Results】 Fever and cough were the main clinical manifestations in all children. The infant group had a significantly higher incidence of wheezing (32.50%) and single viral or bacterial co-infection rate (60.00%) than the other two groups, with single viral infection (40.00%) as the predominant complication. The levels of serum C-reactive protein, neutrophil-to-lymphocyte ratio and lactate dehydrogenase in the preschool and school-age groups were significantly higher than those in the infant group (P<0.05). The median D-dimer level of the three groups showed no obvious elevation compared with the normal range (P>0.05), while significantly increased D-dimer level (median: 25.72 mg/L) was observed in 5 children complicated with pulmonary embolism. Massive pulmonary consolidation was the main imaging feature in all groups, especially in the preschool and school-age groups, which also had a higher proportion of pleural effusion than the infant group (P<0.05). All 5 cases of pulmonary embolism occurred in preschool and school-age children. Extrapulmonary complications occurred in 99 children (47.83%), mainly including liver dysfunction and myocardial injury, with a higher incidence in the infant group. One school-age child developed multi-site vascular embolism and achieved a good prognosis after treatment. The school-age group had higher proportions of children receiving tetracycline antibiotics and undergoing bronchoscopic lavage for no less than twice (P<0.05). A total of 28 children (13.53%) received immune supportive therapy, most of whom were from the infant and school-age groups (23/28). All children improved and were discharged after treatment. 【Conclusion】 There are significant differences in clinical characteristics of children with drug-resistant severe MPP across different age groups. Clinically, individualized diagnosis and treatment strategies should be optimized based on age stratification characteristics to improve the efficacy of clinical treatment.

Key words： Pneumonia, Mycoplasma Drug Resistance, Bacterial Child

Received: 11 February 2026

PACS:

R725.631

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	SUN Hui
	HUANG Han
	DING Xiaofang
	PENG Li
	YU Jingwen

Cite this article:

SUN Hui,HUANG Han,DING Xiaofang, et al. Analysis of Clinical Characteristics of Drug-Resistant Severe Mycoplasma Pneumoniae Pneumonia in Children of Different Age Groups[J]. JOURNAL OF CLINICAL RESEARCH, 2026, 43(6): 881-884.

URL:

http://journal07.magtech.org.cn/yxlcyj/EN/10.3969/j.issn.1671-7171.2026.06.001 OR http://journal07.magtech.org.cn/yxlcyj/EN/Y2026/V43/I6/881

[1] SUN Y M, LI P, JIN R H, et al. Characterizing the epidemiology of Mycoplasma pneumoniae infections in China in 2022-2024: a nationwide cross-sectional study of over 1.6 million cases[J].Emerg Microbes Infect,2025, 14(1): 2482703.
[2] JIANG Y, DOU H W, XU B, et al. Macrolide resistance of Mycoplasma pneumoniae in several regions of China from 2013 to 2019[J].Epidemiol Infect,2024, 152: e75.
[3] ZHENG Y, LI G T, DAI H C, et al. Macrolide-resistant Mycoplasma pneumoniae pneumonia in Chinese children: a retrospective study of clinical features and prognosis[J].Ital J Pediatr,2025, 51(1): 289.
[4] 钱胜华,王晓花,张莉,等. 婴幼儿喘息与肺炎支原体感染的关系探讨[J].中国当代儿科杂志, 2016, 18(11): 1090-1093.
[5] KONG K M, DING Y, WU B R, et al. Clinical predictors of wheezing among children infected with Mycoplasma pneumoniae[J].Front Pediatr,2021, 9: 693658.
[6] CHOO S, LEE Y Y, LEE E. Clinical significance of respiratory virus coinfection in children with Mycoplasma pneumoniae pneumonia[J].BMC Pulm Med,2022, 22(1): 212.
[7] LI C Z, RAO J J, WANG X M, et al. Navigating the outbreak: a comprehensive analysis of pediatric Mycoplasma pneumoniae pneumonia via targeted next-generation sequencing in Wuhan, 2022—2023[J].Microbiol Spectr,2025, 13(5): e0246324.
[8] FREUND Y, COHEN-AUBART F, BLOOM B. Acute pulmonary embolism: a review[J].JAMA,2022, 328(13): 1336-1345.
[9] BRANDÃO L R, LABARQUE V, DIAB Y, et al. Pulmonary embolism in children[J].Semin Thromb Hemost,2011, 37(7): 772-785.
[10] WANG Z Y, PENG Y Y, YANG S, et al. Risk factors for complications of Mycoplasma pneumoniae pneumonia in hospitalized children in China: a systematic review and meta-analysis[J]. BMC Pediatr,2024, 24(1): 810.
[11] HAN C J, ZHANG T Q, ZHENG J F, et al. Analysis of the risk factors and clinical features of Mycoplasma pneumoniae pneumonia with embolism in children: a retrospective study[J].Ital J Pediatr,2022, 48(1): 153.